- Supported exchanges /
- F /
- 2QV0.F
CHEMOMAB THERAP. ADR/20 (2QV0 F) stock market data APIs
Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases in the United States. Its lead product candidate is CM-101, a humanized monoclonal antibody attenuates the basic function of CCL24 that is in phase 2 clinical trial for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). Chemomab Therapeutics Ltd. was founded in 2011 and is based in Tel Aviv, Israel.
CHEMOMAB THERAP. ADR/20 Financial Data Overview
1.32 | |
1.34 | |
- | |
1.34 | |
1.32 | |
0.396-2.02 | |
28 563 K | |
18 857 K | |
0 | |
-0.34 | |
0.293 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
CHEMOMAB THERAP. ADR/20 Fundamental Data is available in our Financial Data APIs
- Net Revenue 0
- EBITDA -15 969 000
- Earnings Per Share -0.98
- Income Statements
- Balance Sheets
- Cash flows
of Fundamental API Data
Get CHEMOMAB THERAP. ADR/20 Earnings via APIs
- Latest Release 2023-09-30
- EPS/Forecast -0.02
Get CHEMOMAB THERAP. ADR/20 End-of-day Data via APIs
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also: